Skip to search formSkip to main contentSkip to account menu

Cardiotoxicity

Known as: Cardiac Toxicities, Toxicity, Cardiac, Cardiac Toxicity 
Toxicity that impairs or damages the heart. This condition is often caused by the administration of a pharmaceutical agent that initiates a poisonous… 
National Institutes of Health

Related topics

Related topics

4 relations
In BloodMicrobiologicalnursing therapyprevention & control

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2005
Highly Cited
2005
Limb salvage with isolated perfusion for soft tissue sarcoma: could less TNF-alpha be better?
BACKGROUND The optimal dose of TNF-alpha delivered by isolated limb perfusion (ILP) in patients with locally advanced soft tissue… 
Highly Cited
1999
Highly Cited
1999
Cisplatin, gemcitabine, and vinorelbine combination therapy in advanced non-small-cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group.
PURPOSE In a previous phase I study cisplatin (CDDP), gemcitabine (GEM), and vinorelbine (VNR) combination therapy was safe and… 
Highly Cited
1996
Highly Cited
1996
Phase II study of paclitaxel in patients with recurrent malignant glioma.
PURPOSE To assess the efficacy and toxicity of paclitaxel administered as a 3-hour infusion to patients with recurrent malignant… 
Highly Cited
1994
Highly Cited
1994
Phase II study on neoadjuvant hyperthermic‐antiblastic perfusion with doxorubicin in patients with intermediate or high grade limb sarcomas
Background. Locoregional control of soft tissue sarcomas of the limbs is achieved generally using a multidisciplinary approach… 
Highly Cited
1985
Highly Cited
1985
Phase I study of vinblastine and verapamil given by concurrent iv infusion.
Overcoming resistance to chemotherapy is an important goal in cancer treatment. In many systems, resistance to anthracyclines and… 
Highly Cited
1984
Highly Cited
1984
Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity
Thirty‐eight patients with a mean age of 53.2 years (19 to 75 years of age), who were receiving doxorubicin (D) for malignant… 
Highly Cited
1983
Highly Cited
1983
Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer.
4-Demethoxydaunorubicin (4-DMDR), an anthracycline analogue available in i.v. and p.o. form, has shown significant antitumor… 
Highly Cited
1977
Highly Cited
1977
Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule, with particular reference to lack of cardiac toxicity
Two hundred and seven patients have been treated using a weekly regimen of Adriamycin in combination with various other… 
Highly Cited
1972
Highly Cited
1972
Cellular immunity to human breast carcinoma
An in vitro microassay technique was used to study the cellular immunological response of 16 breast carcinoma patients against… 
Highly Cited
1972
Highly Cited
1972
The influence of vitamin E on the lung fatty acids of rats exposed to ozone.
The effect of vitamin E on ozone toxicity was Investigated by continuous exposure of rats fed a defined diet Dietary… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)